A phase II study of gefitinib as a first-line therapy for advanced non-small cell lung cancers with epidermal growth factor receptor (EGFR) gene mutations
H Asahina, K Yamazaki, I Kinoshita, S Ogura… - Journal of Clinical …, 2006 - ascopubs.org
13014 Background: Activating mutations in exon 18–21 of the epidermal growth factor
receptor (EGFR) gene have been reported to be a predictor of response to gefitinib. We …
receptor (EGFR) gene have been reported to be a predictor of response to gefitinib. We …
Clinical Impact of Switching to a Second EGFR-TKI After a Severe AE Related to a First EGFR-TKI in EGFR-mutated NSCLC
M Takeda, I Okamoto, J Tsurutani, N Oiso… - Japanese journal of …, 2012 - academic.oup.com
Objective Somatic mutations in the epidermal growth factor receptor gene are associated
with a therapeutic response to epidermal growth factor receptor tyrosine kinase inhibitors …
with a therapeutic response to epidermal growth factor receptor tyrosine kinase inhibitors …
[HTML][HTML] Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for …
H Yoshioka, M Shimokawa, T Seto, S Morita… - Annals of …, 2019 - Elsevier
Background Primary analysis of the phase III study WJTOG 3405 demonstrated superiority of
progression-free survival (PFS) for gefitinib (G) in patients treated with the epidermal growth …
progression-free survival (PFS) for gefitinib (G) in patients treated with the epidermal growth …
First-line gefitinib for patients with advanced non–small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy
A Inoue, K Kobayashi, K Usui, M Maemondo… - Journal of Clinical …, 2009 - ascopubs.org
Purpose This multicenter phase II study was undertaken to investigate the efficacy and
feasibility of gefitinib for patients with advanced non–small-cell lung cancer (NSCLC) …
feasibility of gefitinib for patients with advanced non–small-cell lung cancer (NSCLC) …
Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan …
K Tamura, I Okamoto, T Kashii, S Negoro… - British journal of …, 2008 - nature.com
The purpose of this study was to evaluate the efficacy of gefitinib and the feasibility of
screening for epidermal growth factor receptor (EGFR) mutations among select patients with …
screening for epidermal growth factor receptor (EGFR) mutations among select patients with …
First-or second-line therapy with gefitinib produces equal survival in non–small cell lung cancer
JY Wu, CJ Yu, CH Yang, SG Wu, YH Chiu… - American journal of …, 2008 - atsjournals.org
Rationale: Gefitinib is effective in treating patients with non–small cell lung cancer (NSCLC)
with epidermal growth factor receptor (EGFR) mutations. Deletions in exon 19 and L858R in …
with epidermal growth factor receptor (EGFR) mutations. Deletions in exon 19 and L858R in …
Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer—data from a randomized Phase III study …
E Miyauchi, A Inoue, K Kobayashi… - Japanese Journal of …, 2015 - academic.oup.com
Objective Epidermal growth factor receptor tyrosine kinase inhibitors are effective as first-line
therapy for advanced non-small cell lung cancer patients harboring epidermal growth factor …
therapy for advanced non-small cell lung cancer patients harboring epidermal growth factor …
Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous …
N Sunaga, Y Tomizawa, N Yanagitani, H Iijima, K Kaira… - Lung Cancer, 2007 - Elsevier
PURPOSE: Mutations in the epidermal growth factor receptor (EGFR) gene are associated
with increased sensitivity of non-small cell lung cancer (NSCLC) to gefitinib, an EGFR …
with increased sensitivity of non-small cell lung cancer (NSCLC) to gefitinib, an EGFR …
[HTML][HTML] Comparison of clinical outcomes following gefitinib and erlotinib treatment in non–small-cell lung cancer patients harboring an epidermal growth factor …
SH Lim, JY Lee, JM Sun, JS Ahn, K Park… - Journal of Thoracic …, 2014 - Elsevier
Background: Gefitinib and erlotinib, small-molecule kinase inhibitors that block epidermal
growth factor receptor (EGFR) signaling, have demonstrated a dramatic response rate and …
growth factor receptor (EGFR) signaling, have demonstrated a dramatic response rate and …
Lung adenocarcinoma harboring L858R and T790M mutations in epidermal growth factor receptor, with poor response to gefitinib: A case report
YF Wang, X Xiang, X Pei, S Li, C Tang… - Oncology …, 2014 - spandidos-publications.com
Lung cancer is the leading cause of mortality among malignant diseases in humans
worldwide. During the last decade, molecular targeted therapies for non-small cell lung …
worldwide. During the last decade, molecular targeted therapies for non-small cell lung …